Generic Name and Formulations:
Hydroquinone 2%, ethyldihydroxypropyl PABA 5%, dioxybenzone 3%, oxybenzone 2%; crm; contains sulfites.
Valeant Pharmaceuticals, Inc
Indications for SOLAQUIN:
Hyperpigmented skin conditions.
Apply and massage in twice daily; max 2 months.
Avoid eyes. Use cautiously near lips, eyes, nose. Do 24 hr patch test before use; do not use if itching, vesicle formation, or excessive inflammatory response occurs. Close patient supervision recommended. Discontinue if sensitization occurs. Asthma. Avoid sun or UV light. Pregnancy (Cat.C). Nursing mothers.
Depigmenting agent + sunscreens.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified